Erratum: Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity (Molecular Therapy (2021) 29(5) (1808–1820), (S152500162100071X), (10.1016/j.ymthe.2021.02.004))

Mary K. McKenna, Alexander Englisch, Benjamin Brenner, Tyler Smith, Valentina Hoyos, Masataka Suzuki, Malcolm K. Brenner

Research output: Contribution to journalComment/debatepeer-review

Abstract

(Molecular Therapy 29, 1808–1820; May 5,2021) In the originally published version of this article, a reference to Figure 2 was incorrect in the text, and the Figure 3 legend description was reversed for Figures 3E and 3F. The y-axis in Figure 3E was represented as a percentage rather than a fraction. The data remain unchanged. The figure and legend have now been corrected online. The authors regret this error. [Figure presented] [Figure presented]

Original languageEnglish (US)
Pages (from-to)3529-3533
Number of pages5
JournalMolecular Therapy
Volume29
Issue number12
DOIs
StatePublished - Dec 1 2021

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Erratum: Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity (Molecular Therapy (2021) 29(5) (1808–1820), (S152500162100071X), (10.1016/j.ymthe.2021.02.004))'. Together they form a unique fingerprint.

Cite this